Medical Editor: John P. Cunha, DO, FACOEP
- local reactions such as eye inflammation
- hypotony maculopathy
- vascular reactions
- corneal reactions, and
Each vial of Mitosol contains 0.2 mg of mitomycin and mannitol in a 1:2 concentration ratio. Mitosol is contraindicated in women who are or may become pregnant during therapy and in those who are hypersensitive to mitomycin. Serious side effects include cataract formation and corneal or scleral damage. Mitosol may interact with other drugs. Tell your doctor all medications and supplements you use. Mitosol may cause fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in breastfeeding infants from Mitosol, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. It is recommended that women receiving Mitosol not breast feed because of the potential for serious adverse reactions in nursing infants. The safety and effectiveness of Mitosol in the pediatric population has not been studied.
Our Mitosol Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Ophthalmic Adverse Reactions
The most frequent adverse reactions to Mitosol® occur locally, as an extension of the pharmacological activity of the drug. These reactions include:
Hypotony: choroidal reactions (choroidal detachment, choroidal effusion, serous choroidal detachment, suprachoroidal hemorrhage, hypotony maculopathy, presence of supraciliochoroidal fluid, hypoechogenic suprachoroidal effusion)
Scleritis: wound dehiscence
Additional Reactions: macular edema, sclera thinning or ulceration, intraocular lens capture, disk swelling, malignant glaucoma, lacrimal drainage system obstruction, ciliary block, corneal vascularization, visual acuity decrease, cystic conjunctival degeneration, upper eyelid retraction, dislocated implants, severe loss of vision.
Read the entire FDA prescribing information for Mitosol (Mitomycin)